61-75 of 75
Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
CME/CECurrent Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
William J. Gradishar, MD
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
CME/CEUtilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
William J. Gradishar, MD
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
CME/CEEmploying Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
Robert L. Coleman, MD, FACOG, FACS
Susana Campos, MD, MPH
Domenica Lorusso, MD, PhD
TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
CME/CETROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
Benjamin Levy, MD
Rebecca Heist, MD, MPH
Peter Bela Illei, MD
Evolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment
CME/CEEvolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment
William Mencia, MD, FACEHP
Julie Blatt, MD
Taizo Nakano, MD
Jaffer Ajani, MD
Justin Gainor, MD
Sara A. Hurvitz, MD, FACP
Gopa Iyer, MD
- advertisement
Sara A. Hurvitz, MD, FACP
Gopa Iyer, MD
Jaffer Ajani, MD
Justin Gainor, MD
Sara A. Hurvitz, MD, FACP
Gopa Iyer, MD
- advertisement
Justin Gainor, MD
Justin Gainor, MD
Sara A. Hurvitz, MD, FACP